✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic HivResearchDrug InteractionsNeuropathyAppetite Why This MattersAcademic research positions dedicated to cannabis-HIV intersections signal growing institutional...
Cannabis Trial in HIV Patients Fell Far Short of Enrollment Goals, Revealing Key Barriers to Cannabinoid Research
Two hundred and five individuals were approached, and 10 consented and were randomized; the rest refused (reasons: cannabis-related stigma/discomfort; too many study visits/insufficient time; unwillingness to undergo a ‘washout period’ for three weeks) or were not eligible.
One in Four Women with HIV Used Cannabis in 18 Months, With Most Relying on Smoking
The period prevalence was 27% for any cannabis use and 15% for daily or more use. Among women using cannabis, 96% reported smoking, 30% consumed edibles, and 18% vaped.
`Cannabinoid Clinical Trials: HIV Smoking Cessation Data`
Clinical Takeaway A digital therapeutic tailored specifically for people living with HIV showed feasibility and acceptability as a smoking cessation tool, suggesting this population can be reached and engaged through technology-based interventions....
Study: Low-Dose CBD Found Safe for People With HIV on Long-Term Antiretroviral Therapy …
✦ New CED Clinical Relevance #80High Clinical Relevance Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News | CED Clinic HivDrug InteractionsCbdImmunologySafety Why This MattersHIV patients on antiretroviral therapy often experience complex polypharmacy...
Mapping the Gaps: What We Know—and Don’t Know—About Cannabis for Symptom Management in HIV and Cancer
There are limited metrics on the perceived effectiveness and safety of cannabis use for symptom management and its dosing/mode of delivery for reducing symptoms.
Cannabis for HIV and Cancer Symptom Management: A Scoping Review Finds Promising Signals but Major Evidence Gaps
There are limited metrics on the perceived effectiveness and safety of cannabis use for symptom management and its dosing/mode of delivery for reducing symptoms.
Major Gaps Found in Research on Cannabis for Symptom Relief in HIV and Cancer Patients
There are limited metrics on the perceived effectiveness and safety of cannabis use for symptom management and its dosing/mode of delivery for reducing symptoms.
Cannabis for Symptom Relief in HIV and Cancer: A Map of What We Know—and What We Don’t
There are limited metrics on the perceived effectiveness and safety of cannabis use for symptom management and its dosing/mode of delivery for reducing symptoms.
Endocannabinoid System Research: Cannabis & HIV Smoking
Clinical Takeaway Digital therapeutics tailored to people living with HIV show promising feasibility and acceptability as a scalable approach to smoking cessation in this high-risk population. Tobacco use remains a leading driver...